Adjuvant Trials
NRG-BR003 – A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin in Women with Node-Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer.

NSABP B53/S1207 - Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.

NSABP B-55 - A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy.

Neo-Adjuvant Breast Trials
NSABP B-52 - A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation.                        

Metastatic Breast Trials
ML28257-A2- SystHER2 - An Observational Cohort Study of Treatment Patterns and Outcomes In Patients With HER2 Positive (HER2+) Metastatic Breast Cancer.

E2112 - A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer.

NUCLEA – Longitudinal Evaluatio of Serum HER-2 Protein Levels in Patients with Metastatic Breast Carcinoma.